Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
A phase 1/2 trial of Gemcitabine in pancreatic ductal adenocarcinoma, run by BeyondBio Inc., now recruiting.
Overview
Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer is a phase 1/2 interventional study registered as NCT03579836 by BeyondBio Inc., with 75 participants planned, started 2018-05-14 and due to reach its primary completion in 2026-11-30. Interventions recorded: BEY1107 and Gemcitabine.
Similar pages
not linked directly; found by shared links- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialIntra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialClinical Study of Tumor Treating Fields Combined with Gemcitabine and Albumin-bound Paclitaxel in the First-line Treatment of Locally Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialSafety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialA Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.
- TrialIN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer
Shares Gemcitabine, Pancreatic ductal adenocarcinoma and the tag pipeline.